IPF is a chronic lung disease with fibrous tissue formation, leading to respiratory decline and poor prognosis, affecting mainly older adults. Diagnosis is challenging due to its exclusionary nature, ...

A new risk stratification model for idiopathic pulmonary fibrosis could shift treatment from passive monitoring to active, goal-oriented care.

Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis. There are several agents with new mechanisms of action in the pipeline for idiopathic pulmonary fibrosis (IPF).

Please provide your email address to receive an email when new articles are posted on . An online survey was created to capture the burden of IPF. Patients frequently reported shortness of breath. IPF ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Gersten: I've ...

HealthDay News — Recommendations for idiopathic pulmonary fibrosis (IPF) treatment have been updated by an international group of respiratory societies. The updated clinical practice guideline was ...

Deupirfenidone, a potential new treatment for idiopathic pulmonary fibrosis, is set to be tested in a phase 3 trial this year after a successful phase 2b trial and meeting with the FDA, according to a ...

FibroGen is focused on developing pamrevlumab, an innovative drug with potential for IPF treatment, which could capture a share of the multi-billion dollar IPF drug market. The PRAISE study showed ...